The Group recorded a significant +15% on the Italian market in the first three months of the current year, thanks […]
The Group obtains approval of the CetilarĀ®Ā patent in the USA and new prospects unfold for SiderALĀ® in India thanks to […]
The Board of Directors approves the draft balance sheet and consolidated financial statement as of 31 December 2019. […]
As we all know, the spread of COVID-19 has led to a series of restrictive measures being taken by the […]
The Group will supply the products SiderALĀ® H and ApportALĀ® free of charge to the intensive care units of all […]
At this complex time for the market, PharmaNutra is strengthening its investment plan with the launch of a new campaign. […]